PE20020591A1 - Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion - Google Patents
Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccionInfo
- Publication number
- PE20020591A1 PE20020591A1 PE2001001179A PE2001001179A PE20020591A1 PE 20020591 A1 PE20020591 A1 PE 20020591A1 PE 2001001179 A PE2001001179 A PE 2001001179A PE 2001001179 A PE2001001179 A PE 2001001179A PE 20020591 A1 PE20020591 A1 PE 20020591A1
- Authority
- PE
- Peru
- Prior art keywords
- isothiazole
- benzyloxy
- difluoro
- bromo
- ilbutyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
SE REFIERE A LA SAL HIDROBROMURO O HEMICITRATO O ACETATO, O p-TOSILATO O L-TARTRATO O HEMISUCCINATO DE AMIDA DE ACIDO 3-(4-BROMO-2,6-DIFLUORO-BENCILOXI)-5-[3-(4-PIRROLIDIN-1-ILBUTIL)UREIDO]ISOTIAZOL-4-CARBOXILICO QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UN METODO PARA PREPARAR LA SAL QUE COMPRENDE MEZCLAR EL ACIDO CON EL COMPUESTO RESPECTIVAMENTE. EL COMPUESTO PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS COMO CANCER CEREBRAL, EPIDERMOIDE, DE VEJIGA, GASTRICO, PANCREATICO, DE MAMA, DE CABEZA, DE CUELLO, ESOFAGAL, DE PROSTATA, COLORECTAL, DE PULMON, RENAL, RINON, OVARICO, GINECOLOGICO, DE TIROIDES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25351300P | 2000-11-28 | 2000-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020591A1 true PE20020591A1 (es) | 2002-07-06 |
Family
ID=22960587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001001179A PE20020591A1 (es) | 2000-11-28 | 2001-11-26 | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion |
Country Status (50)
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
BR0312798A (pt) * | 2002-07-25 | 2005-05-03 | Pfizer Prod Inc | Derivados de isotiazol úteis como agentes anticancerìgenos |
AP2005003232A0 (en) * | 2002-08-19 | 2005-03-31 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases. |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
RU2317295C1 (ru) * | 2003-10-27 | 2008-02-20 | Мерк Энд Ко., Инк. | Соль антагониста ccr-2 |
EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
WO2005102327A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Dosage forms and methods of treatment using vegfr inhibitors |
JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
TW200538104A (en) * | 2004-05-17 | 2005-12-01 | Pfizer Prod Inc | Phenyl derivatives for the treatment of abnormal cell growth |
EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
SI2044043T2 (sl) | 2006-06-16 | 2021-04-30 | H. Lundbeck A/S | 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje |
US7932390B2 (en) | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
MX2010001636A (es) | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
CA2806921C (en) | 2010-07-23 | 2019-11-26 | Trustees Of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
EP2968650B1 (en) * | 2013-03-14 | 2019-01-16 | PanOptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
EP3193867B1 (en) * | 2014-09-17 | 2021-01-20 | PanOptica, Inc. | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
-
2001
- 2001-11-19 KR KR1020057022534A patent/KR20050116401A/ko active IP Right Grant
- 2001-11-19 ES ES01982663T patent/ES2271086T3/es not_active Expired - Lifetime
- 2001-11-19 JP JP2002546528A patent/JP2004514714A/ja not_active Withdrawn
- 2001-11-19 AU AU1420402A patent/AU1420402A/xx active Pending
- 2001-11-19 DK DK01982663T patent/DK1337521T3/da active
- 2001-11-19 HU HU0302553A patent/HUP0302553A3/hu unknown
- 2001-11-19 NZ NZ525788A patent/NZ525788A/en unknown
- 2001-11-19 CZ CZ20031315A patent/CZ20031315A3/cs unknown
- 2001-11-19 YU YU36403A patent/YU36403A/sh unknown
- 2001-11-19 OA OA1200300137A patent/OA12532A/en unknown
- 2001-11-19 IL IL15537101A patent/IL155371A0/xx unknown
- 2001-11-19 AT AT01982663T patent/ATE340786T1/de not_active IP Right Cessation
- 2001-11-19 AU AU2002214204A patent/AU2002214204B2/en not_active Ceased
- 2001-11-19 UA UA2003054858A patent/UA74221C2/uk unknown
- 2001-11-19 KR KR10-2003-7007057A patent/KR20030059275A/ko not_active Application Discontinuation
- 2001-11-19 WO PCT/IB2001/002193 patent/WO2002044158A1/en active IP Right Grant
- 2001-11-19 EE EEP200300247A patent/EE200300247A/xx unknown
- 2001-11-19 PT PT01982663T patent/PT1337521E/pt unknown
- 2001-11-19 CN CNB018193285A patent/CN1231474C/zh not_active Expired - Fee Related
- 2001-11-19 BR BR0115621-7A patent/BR0115621A/pt not_active Application Discontinuation
- 2001-11-19 SK SK586-2003A patent/SK5862003A3/sk unknown
- 2001-11-19 PL PL01362079A patent/PL362079A1/xx not_active Application Discontinuation
- 2001-11-19 MX MXPA03004714A patent/MXPA03004714A/es active IP Right Grant
- 2001-11-19 EP EP01982663A patent/EP1337521B1/en not_active Expired - Lifetime
- 2001-11-19 GE GE5216A patent/GEP20053652B/en unknown
- 2001-11-19 AP APAP/P/2001/002358A patent/AP2001002358A0/en unknown
- 2001-11-19 DE DE60123461T patent/DE60123461T2/de not_active Expired - Lifetime
- 2001-11-19 CA CA002430065A patent/CA2430065C/en not_active Expired - Lifetime
- 2001-11-19 EA EA200300424A patent/EA005859B1/ru not_active IP Right Cessation
- 2001-11-19 DO DO2001000288A patent/DOP2001000288A/es unknown
- 2001-11-19 SI SI200130630T patent/SI1337521T1/sl unknown
- 2001-11-26 MY MYPI20015382A patent/MY136686A/en unknown
- 2001-11-26 AR ARP010105484A patent/AR031512A1/es not_active Application Discontinuation
- 2001-11-26 UY UY27039A patent/UY27039A1/es not_active Application Discontinuation
- 2001-11-26 PE PE2001001179A patent/PE20020591A1/es not_active Application Discontinuation
- 2001-11-27 SV SV2001000748A patent/SV2002000748A/es unknown
- 2001-11-27 TN TNTNSN01167A patent/TNSN01167A1/fr unknown
- 2001-11-27 TW TW090129315A patent/TWI287542B/zh active
- 2001-11-27 PA PA20018533801A patent/PA8533801A1/es unknown
- 2001-11-27 GT GT200100237A patent/GT200100237A/es unknown
- 2001-11-27 HN HN2001000268A patent/HN2001000268A/es unknown
- 2001-11-27 US US09/993,640 patent/US6831091B2/en not_active Expired - Lifetime
-
2003
- 2003-04-14 IS IS6788A patent/IS6788A/is unknown
- 2003-04-22 BG BG107752A patent/BG107752A/bg unknown
- 2003-04-24 CR CR6963A patent/CR6963A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303341A patent/ZA200303341B/en unknown
- 2003-05-13 MA MA27158A patent/MA26960A1/fr unknown
- 2003-05-20 HR HR20030408A patent/HRP20030408A2/hr not_active Application Discontinuation
- 2003-05-27 NO NO20032388A patent/NO325187B1/no unknown
- 2003-05-28 EC EC2003004628A patent/ECSP034628A/es unknown
-
2004
- 2004-03-22 HK HK04102071A patent/HK1059085A1/xx not_active IP Right Cessation
-
2006
- 2006-11-13 CY CY20061101645T patent/CY1106240T1/el unknown
-
2007
- 2007-10-29 JP JP2007279951A patent/JP4971946B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020591A1 (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion | |
SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
EA200701219A1 (ru) | Способ получения титана | |
RU97104165A (ru) | Спиро-азабициклические соединения, полезные в терапии | |
WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
SG155046A1 (en) | Process for modifying drug crystal formation | |
RU2010107795A (ru) | Бициклические амиды для усиления глутаматергических синаптических ответов | |
WO2016018795A1 (en) | Histone deacetylase inhibitors | |
AR112683A1 (es) | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende | |
TW200635905A (en) | Processes for producing 4-aminoquinazolines | |
MX2023003362A (es) | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. | |
SI1656381T1 (sl) | Kristalizacija trdnih oblik adicijskih soli klopidogrela | |
WO2008136863A3 (en) | Synthesis of compounds useful as modulators of amyloid-beta production | |
HUP0004805A2 (hu) | Lényegében vízmentes habosítószer és eljárás ennek előállítására | |
PL1643854T3 (pl) | Sposób poprawiania jakości tkanek zwierzęcych przez uzupełnienie diety zwierząt o mieszane tokotrienole | |
EA200501734A1 (ru) | Способ получения (4-гидрокси-6-оксотетрагидропиран-2-ил)ацетонитрила и его производных | |
ATE486867T1 (de) | Verfahren zur herstellung von hochreinem meloxicam und meloxicam-kaliumsalz | |
BRPI0409235A (pt) | processo para a produção de sal de amÈnio do ácido 2-hidróxi-4-metiltiobutìrico | |
BR0214971A (pt) | Processo para a produção de um imunossupressor | |
CA2797442A1 (en) | Process for the production of ferrous sulphate monohydrate | |
GB0417063D0 (en) | Process for the preparation of optically-active compounds | |
CN108017550B (zh) | 一种3-氨基-1,2-丙二醇生产工艺 | |
BRPI0405609A (pt) | Métodos de produção e de avaliação de um pirrolidonacarboxilato de zinco di-hidratado, pirrolidonacarboxilato de zinco di-hidratado, e, cosmético |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |